Glucocorticoid
Oral nonsteroidal treatment reduces glucocorticoid dose in congenital adrenal hyperplasia
Adults with congenital adrenal hyperplasia receiving an oral corticotropin-releasing factor type 1 receptor antagonist had a greater reduction in daily glucocorticoid dose at 24 weeks than placebo, according to top-line phase 3 trial data.
Low-dose glucocorticoids for rheumatoid arthritis lead to small weight gain
When taken over 2 years for rheumatoid arthritis, low-dose glucocorticoids were associated with slight weight gain, but they did not significantly affect BP, according to research published in Annals of Internal Medicine.
‘Lipid paradox’ may obscure cardiovascular risk in patients with inflammatory disease
AUSTIN, Texas — Providers should carefully consider the “lipid paradox” when monitoring cardiovascular risks in patients with rheumatic inflammatory diseases, noted a presenter at the 2023 Rheumatology Nurses Society annual conference.
Adults hospitalized with COVID-19 have lower thyroglobulin levels with glucocorticoid use
Thyroglobulin levels differed by glucocorticoid use, but not by thyroid function, among a cohort of adults hospitalized for COVID-19, according to findings published in Frontiers in Endocrinology.
Addressing glucocorticoid withdrawal syndrome in treatment of Cushing’s syndrome
To achieve optimal outcomes in Cushing’s syndrome, both clinicians and patients need to be prepared for the type and duration of symptoms that patients may experience during treatment and recovery.
Central nervous system vasculitis treatment strategies still lack strong data
Current treatment strategies for patients with central nervous system vasculitis are not based on high-grade scientific evidence but rather expert opinion, according to a speaker at the Biologic Therapies Summit.
Patients with ANCA-associated vasculitis remain ‘soaked in steroids’ despite new therapies
DESTIN, Fla. — Despite advances in biologic therapies, “excess steroid use” remains a mainstay of treatment for patients with ANCA-associated vasculitis, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.
Top in rheumatology: Tocilizumab for giant cell arteritis; glucocorticoids for MIS-C
The European Alliance of Associations for Rheumatology issued updated guidance recommending weekly tocilizumab, along with glucocorticoids that should eventually be tapered, for patients with new, relapsing giant cell arteritis.
MIS-C outcomes with glucocorticoids alone similar to IVIG, combination therapy
Glucocorticoids alone demonstrate similar recovery rates as intravenous immunoglobin, or combination therapy with both, in patients with multisystem inflammatory syndrome in children, according to data published in The Lancet Rheumatology.
Trabecular bone score less useful bone strength biomarker than BMD for older adults
Antiresorptive medications such as oral bisphosphonates have a minimal effect on change in lumbar spine trabecular bone score among older adults, according to a study published in The Journal of Bone and Mineral Research.